PILR-alpha (paired immunoglobulin-like type 2 receptor-alpha; also named FDF03) is one of two members of a small family of immunoregulatory Ig-superfamily receptors. It is a counterpart to PILR-beta and it likely gave rise to PILR-beta through gene duplication and rearrangement. The PILRs represent one of many pairs of Ig-like domain-containing receptors that participate in immune regulation. PILR-alpha and -beta should not be confused with the similarly named PIRs (also paired immunoglobulin-like receptors), or the functionally-related SIRP and ILT/LILR/CD85/LIR family of receptors. While PIRs, ILTs and SIRPs contain three to six Ig-like domains in their extracellular region, PILR-alpha and -beta show only one Ig-like region in their extracellular domain (ECD). Mouse PILR-alpha is a monomeric, 271 amino acid (aa) type I transmembrane (TM) protein. It contains a 167 aa ECD, a 21 aa TM segment, and a long, 83 aa cytoplasmic region. The ECD shows one V-type Ig-like domain between aa 39-157, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyr-based inhibitory motifs) between aa 265-270 and 294-299. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs makes mouse PILR-alpha an inhibitory receptor. In human, activation of PILR-alpha inhibits CD32/Fc gamma RII-induced calcium mobilization. Although CD99 is a known ligand for both PILR-alpha and -beta, highest affinity binding seems to occur between CD99 and PILR-alpha. Mouse PILR-alpha is found on neutrophils and macrophages. Mouse PILR-alpha ECD is 43% and 69% aa identical to human and rat PILR-alpha ECD, respectively; it is 75% aa identical to the ECD of mouse PILR-beta. One potential isoform of PILR-alpha has been reported. It varies only within the first 28 aa of the signal sequence.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.